Mylan and several major drugmakers such as Israel’s Teva Pharmaceutical Industries and India’s Sun Pharmaceutical Industries have been under the DOJ’s scanner for more than eight years over alleged anticompetitive business practices in fixing prices of certain generic drugs.
Tag Archive for: Teva
The Federal Trade Commission has opened an investigation into Teva Pharmaceuticals after the company allegedly ignored directives to withdraw or amend contentious patent listings on the FDA’s Orange Book.
Teva Pharmaceuticals sued rival drugmaker Corcept Therapeutics in federal court in San Francisco, accusing it of monopolizing the market for mifepristone-based Korlym, used to treat a rare hormonal disorder called Cushing’s syndrome.
Despite weathering a difficult year, biopharma continues to see massive pay gaps between CEOs and their median employees, with top executives often earning hundreds of times more.
The companies hope that the drug – an under-the-skin version of a generic antipsychotic medicine called olanzapine – can be used as a once-monthly treatment for patients with the chronic mental disorder.
Like its branded reference product, Selarsdi is a subcutaneous injection that can be used to treat moderate-to-severe plaque psoriasis and active psoriatic arthritis in pediatric and adult patients. Unlike Stelara, however, Selarsdi is not approved for Crohn’s disease and ulcerative colitis.
The U.S. Court of Appeals for the Federal Circuit on Monday ruled in favor of Teva Pharmaceuticals and Viatris, finding that the final Johnson & Johnson patent over its schizophrenia drug Invega Sustenna is invalid.
The FDA on Friday approved Alvotech and Teva’s Simlandi (adalimumab-ryvk), a biosimilar to AbbVie’s blockbuster antibody therapy Humira (adalimumab), ending a long and difficult regulatory road for the partners.
The world’s largest generic drugs maker announced on Wednesday that it will divest its active pharmaceutical ingredient (API) unit to focus on its core business.
Drugmaker Eli Lilly convinced a federal judge in Massachusetts on Tuesday to overturn a $176.5 million jury verdict for Teva Pharmaceutical that found Lilly’s migraine drug Emgality infringed three patents related to Teva’s rival drug Ajovy.